However, the efficacy of GDNF as a therapeutic in PD cannot be assessed from failed ICV or CED clinical trials, because these trans-cranial delivery approaches did not result in adequate GDNF delivery to the brain (Pardridge, 2022b). This evidence concerns the gene GDNF and Parkinson disease.